Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $56.3750.
A number of analysts have recently commented on IMCR shares. Weiss Ratings restated a "sell (e+)" rating on shares of Immunocore in a report on Friday, July 17th. JPMorgan Chase & Co. started coverage on shares of Immunocore in a report on Friday, August 21st. They issued an "overweight" rating and a $50.00 price objective on the stock. Zacks Research raised shares of Immunocore from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 5th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a research report on Monday, July 13th. Finally, Morgan Stanley set a $43.00 price objective on shares of Immunocore in a report on Friday, August 7th.
Check Out Our Latest Stock Analysis on Immunocore
Immunocore Trading Down 1.0%
IMCR opened at $36.75 on Friday. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. Immunocore has a 52 week low of $27.56 and a 52 week high of $40.71. The stock has a market cap of $1.89 billion, a PE ratio of -99.32 and a beta of 0.74. The business has a 50 day moving average of $33.65 and a 200-day moving average of $31.57.
Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. Equities research analysts predict that Immunocore will post 0.06 earnings per share for the current fiscal year.
Institutional Trading of Immunocore
A number of institutional investors have recently made changes to their positions in the stock. denkapparat Operations GmbH purchased a new position in shares of Immunocore during the second quarter valued at approximately $209,000. Braidwell LP bought a new position in Immunocore during the second quarter valued at approximately $16,552,000. Headlands Technologies LLC purchased a new stake in Immunocore in the second quarter worth approximately $290,000. Public Employees Retirement System of Ohio purchased a new stake in Immunocore in the second quarter worth approximately $2,145,000. Finally, Hennion & Walsh Asset Management Inc. grew its position in Immunocore by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,324 shares of the company's stock worth $1,534,000 after purchasing an additional 1,197 shares during the period. Hedge funds and other institutional investors own 84.50% of the company's stock.
Immunocore Company Profile
(
Get Free Report)
Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body's own T‐cell response to treat cancer and infectious diseases. The company's proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.
The company's most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
